MyLab Discovery Solutions’ COVID-19 Antigen Testing Kit Pathocatch Gets Commercial Approval From ICMR

MyLab’s kit named Pathocatch will be priced at Rs 450 and will be available for orders immediately.

Mylab Discovery Solutions, a molecular diagnostics company, is now all set to launch its antigen testing kits with commercial approval from the Indian Council of Medical Research (ICMR). It must be noted that Mylab Discovery Solutions had launched the first indigenous RT-PCR testing kit.

It will be the first Indian firm to get approval from the ICMR that has developed the kit in India and will be making it here too. The company has a plant in Manesar.

MyLab’s kit named Pathocatch will be priced at Rs 450 and will be available for orders immediately.

At present, Korean company SD Biosensor is the only firm approved by ICMR for these kits.

“The launch of the antigen testing kit is in line with the government’s expectation to increase rapid testing, which is the point-of-care method and complements the more rigorous RT-PCR test to detect coronavirus,” the company said.

“Mylab team is working really hard to fight this pandemic in every possible way. After bringing an affordable RT-PCR test to reduce dependence on foreign kits, we launched Compact XL to accelerate COVID-19 testing. Now, with the approval for an antigen testing kit, we will cover the whole spectrum of COVID-19 testing and leave no stone unturned to fight this pandemic,”
Hasmukh Rawal, MD, Mylab Discovery Solutions was quoted as saying by a news website.

The approval comes at a time when the number of COVID-19 infection cases is increasing across the country and more states are allowing antigen-based rapid testing in India.

India is using a combination of both antigen and RT-PCR testing as its testing strategy. This will save both time and cost, speeding up the process of testing and isolation. Meanwhile, India’s COVID-19 case count crossed the 12 lakh mark on Wednesday.

In a related news, Serum Institute of India, the world’s largest vaccine manufacturer by volume, is hopeful of developing a COVID-19 vaccine by October/November this year.

Facebook Comments